A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer (NCT07117461)
A Pilot Distress Screening and Referral Program to Detect Comorbid Psychosocial Distress in NYC Safety Net Hospitals Serving Diverse and Underserved Patients Diagnosed With Cancer
🩺 Plain-English Summary (8th-Grade Level)
It is recommended that cancer centers screen patients for distress and refer them to mental health services when their distress levels reach a certain level. However, many cancer centers don't have distress screening and referral programs. This study will provide valuable information about one distress screening and referral program and whether it can be helpful for a large and diverse group of cancer patients that includes both English- and Spanish-speaking patients.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
- NCCN Distress Thermometer (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Medisys Health Network (Data Collection Only) — Richmond Hill, New York
📞 Contact the Study Coordinator
Phone: (646) 888-8361
Email: jutagird@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor Cancer
- Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing — Detroit, Michigan
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors — Santa Monica, California
- BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) — San Francisco, California
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) — Gilbert, Arizona
Explore by condition: All Solid Tumor Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.